Search results
Dow Jones Futures: Market Rally Narrows; Dow Giants Lead 7 Stocks Near Buy Points
Investor's Business Daily· 1 hour agoThe Dow Jones and Russell 2000 had solid losses as consumer, housing, commodity and software names...
Merck KGaA to buy gene therapy tools maker for $600M
BioPharma Dive via Yahoo Finance· 1 day agoDive Brief: German drugmaker Merck KGaA agreed to buy Mirus Bio for $600 million to build expertise in a critical part of viral vector-based gene therapy...
Merck’s MilliporeSigma agrees to acquire Mirus Bio for $600m
Pharmaceutical Technology via Yahoo Finance· 1 day agoMerck KGaA’s Life Science business in the US and Canada, MilliporeSigma, has entered a definitive...
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks via Yahoo Finance· 4 days agoMerck MRK boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda...
Fed Inflation Gauge, Key Earnings Highlight Investing Action Plan
Investor's Business Daily· 2 hours agoLate in the week, the Fed's favorite inflation gauge, the core PCE price index, will be on tap....
McKesson, Merck back Atropos Health’s $33M round to accelerate drug development with AI
VentureBeat· 1 day agoAtropos Health, a healthcare technology company focused on generating personalized real-world...
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79%
Simply Wall St. via Yahoo Finance· 3 days agoKey Insights Institutions' substantial holdings in Merck implies that they have significant...
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
Investor's Business Daily· 3 hours agoMerus stock catapulted to a record high Friday after its experimental regimen for head-and-neck...
3 Stocks That Can Help You to Get Richer in 2025 and Beyond
Motley Fool via Yahoo Finance· 11 hours ago(For example, it helps drug companies manage their clinical trials.) Its myriad customers include...
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via Yahoo Finance· 3 hours agoKeytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract...